PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Linder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/P	то		C mplete if Known			
•				Application Number	10/088,724		
INFO	RMATION	N DISCL	OSURE	Filing Date	March 18, 2002		
STAT	STATEMENT BY APPLICANT			First Named Inventor	Nishimoto		
				Art Unit	Unassigned		
	(use as many s	heets as nece	essary)	Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	082377-000000US		

L			U.S. PATENT DO	JCOMEN 12	
		Document Number		1	
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KID!					
₩	7				MECENIA
	2		•	·	
2 6 200	4		•		AUC
I ZIUIZ			***		AUG 1 6 2002
	<i>3</i>				
- A	5/				TECH CENTER 400
CADEMAN					TENT VENTER IRAA

	FOREIGN PATENT DOCUMENTS								
C	0.11-	For	eign Patent Doc	ument		Name of Patentee or	Pages, Columns, Lines,		
Examiner Initials*	Cite No. ¹	Country Code ³	Number ⁴	Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T [®]	
or	AA	wo	01/21786	Al -	03-29-2001			yes	
ol	AB	wo	00/14204	A1 -	03-16-2000			yes	
								 	

Examiner Signature	allysmi	Date Considered	3/11/4	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/\$B/08B (10-01) =

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/088,724 INFORMATION DISCLOSURE **Filing Date** March 18, 2002 STATEMENT BY APPLICANT First Named Inventor Nishimoto Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet Attorney Docket Number 082377-000000US

			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
01,	o to	AC 1	BRENNEMAN et al., "Activity-Dependant Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides," J. Pharmacology Exp. Therapeutics, 285(2): 619-627 (1998).	
JUN 2 6 2	JC4	AD	BRENNEMAN et al., "A Femtomolar-acting Neuroprotective Peptide," <u>J. Clinical Investigation</u> , 97(10): 2299-2307 (1996).	
PATERIAL PROCESSES	\$ 00	AE	DORE et al., "Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity," PNAS, 94:4772-4777 (1997).	
PADEMAR	,	AF	GUO et al., "Calbindin D28k blocks the proapoptotic actions of mutant presentilin 1: Reduced oxidative stress and preserved mitochondrial function," PNAS, 95: 3227-3232 (1998).	
		AG	GUO et al., "Secreted β-Amyloid Precursor Protein Counteracts the Proapoptotic Action of Mutant Presenilin-1 by Activation of NF - κB and Stabilization of Calcium Homeostasis*," J. Biological Chemistry, 273(20):12341-12351 (1998).	
		ΑН	MARK et al., "Basic FGF attenuates amyloid β-peptide-induced oxidative stress, mitchondrial dysfunction, and impairment of Na+ /K+-ATPase activity in hippocampal neurons," <u>Brain Research</u> , 756:205-214 (1997).	
	,			

				_
Examiner Signature	lleufshw	Date Considered	3/11/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3230118 v1

_

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

JUN 0 6 2003

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	N S	Older are rapely	WIN NOULCOUT	ACIOI 1950, NO DEISOIS	ale required to respond to a correction of	or information unless it contains a var	d Civib control number.
۴	Substitut	e for form 1449/PT0)			Complete if Known	RECENTER
					Application Number	10/088,724	- VED
		RMATION			Filing Date	June 14, 2002	JUN-A
	STA	TEMENT E	BY APP	LICANT	First Named Inventor	NISHIMOTO, Ikuo	2014 0 9 2003
					Art Unit	1646	Trou
_		(use as many st	neets as nec	essary)	Examiner Name	Unassigned	TECH CENTER 1600 (0
/	Page	1.	of	2	Attorney Docket Number	082377-000000US	290(2900
/	Page	1.	of	2	Attorney Docket Number	082377-000000US	29(

			U.S. PATENT DO	OCUMENTS					
Document Number									
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
									
					-				
				<u></u>					
				1					

				FORE	IGN PA	TENT DOCUME	NTS		
Examiner Cite No.1		For	eign Patent Dod	ument				Pages, Columns, Lines,	
	Country Code 3	Number ⁴	Kind Cod	e ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰	
	AA	wo	01/76532		A2	10-18-2001			
00	AB	wo	98/15179	- Services	Al	04-16-1998			
	AC	wo	97/27296	1	Al	07-31-1997			
		<u> </u>							
		1							

Examiner Signature	lleyson	Date Considered	3/11/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here If English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO Complete if Known **Application Number** 10/088,724 INFORMATION DISCLOSURE **Filing Date** June 14, 2002 STATEMENT BY APPLICANT First Named Inventor NISHIMOTO, Ikuo Art Unit 1646 (use as many sheets as necessary) **Examiner Name** Unassigned

Attorney Docket Number

082377-000000US

Page

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner T² item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No.1 Initials * number(s), publisher, city and/or country where published. ol AD XP-02230776, "Homo sapiens mitochondrial DNA, complete genome," (2000).

Examiner	Muland	Date	3/4/04
Signature	July on	Considered	9/11/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINEX: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line inrough chauch in not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete including Comments on the amount of time you require to complete including Comments on the amount of time you require to complete including Comments on the Section of the Chief Information Comments on the Amount of time you require to complete including the Chief Information Comments on the amount of time you require to complete including the Chief Information Comments on the amount of time you require to complete including the Chief Information Comments on the amount of time you require to complete including the Chief Information Comments on the amount of time you require to complete including the Chief Information Comments on the Chief Information Comments on the comments of Comments on the Chief Information Comments on the Chief the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of the Paperwork Peduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complet if Known 10/088,724 Applicati n Number INFORMATION DISCLOSURE Filing Date March 18, 2002 STATEMENT BY APPLICANT First Named Invent r Nishimoto Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet Attorney Docket Number 082377-000000US

	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	iminer Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue		
	MATTSON et al., "Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presentlin-1," NeuroReport, 8:3817-3821 (1997).	AA	W	
	RECEI			
1	-9_1			
de	AUG 1 6 2			
	TECH CENTER 10	-		
			-	
1				

Examiner Signature	Mufsm	Date Considered	3/11/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3233848 v1

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.